美国镭学会低级别胶质瘤适当使用标准的更新：整合 IDH 抑制剂。

IF 4.9 1区医学 Q1 ONCOLOGY

Radiotherapy and Oncology Pub Date : 2024-11-16 DOI:10.1016/j.radonc.2024.110640

Martin C Tom, Seema Nagpal, Joshua D Palmer, William G Breen, Erqi L Pollom, Eric J Lehrer, Tresa M McGranahan, Kevin Shiue, Anupama Chundury, Shearwood McClelland Iii, Hina Saeed, Eric L Chang, Veronica L S Chiang, Tony J C Wang, Jonathan P S Knisely, Samuel T Chao, Michael T Milano

{"title":"美国镭学会低级别胶质瘤适当使用标准的更新：整合 IDH 抑制剂。","authors":"Martin C Tom, Seema Nagpal, Joshua D Palmer, William G Breen, Erqi L Pollom, Eric J Lehrer, Tresa M McGranahan, Kevin Shiue, Anupama Chundury, Shearwood McClelland Iii, Hina Saeed, Eric L Chang, Veronica L S Chiang, Tony J C Wang, Jonathan P S Knisely, Samuel T Chao, Michael T Milano","doi":"10.1016/j.radonc.2024.110640","DOIUrl":null,"url":null,"abstract":"The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2-3 glioma.","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":" ","pages":"110640"},"PeriodicalIF":4.9000,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An update to the American Radium Society's appropriate use criteria of lower grade Gliomas: Integration of IDH inhibitors.\",\"authors\":\"Martin C Tom, Seema Nagpal, Joshua D Palmer, William G Breen, Erqi L Pollom, Eric J Lehrer, Tresa M McGranahan, Kevin Shiue, Anupama Chundury, Shearwood McClelland Iii, Hina Saeed, Eric L Chang, Veronica L S Chiang, Tony J C Wang, Jonathan P S Knisely, Samuel T Chao, Michael T Milano\",\"doi\":\"10.1016/j.radonc.2024.110640\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2-3 glioma.\",\"PeriodicalId\":21041,\"journal\":{\"name\":\"Radiotherapy and Oncology\",\"volume\":\" \",\"pages\":\"110640\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2024-11-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiotherapy and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.radonc.2024.110640\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiotherapy and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.radonc.2024.110640","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

ARS脑委员会建议，Vorasidenib可能适用于复发或残留的IDH突变2级少突胶质细胞瘤或星形细胞瘤。沃拉西地尼通常不适用于完全切除的2级少突胶质细胞瘤或星形细胞瘤、任何3级少突胶质细胞瘤或星形细胞瘤，或与放疗和/或化疗联合治疗任何2-3级胶质瘤。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

An update to the American Radium Society's appropriate use criteria of lower grade Gliomas: Integration of IDH inhibitors.

The ARS brain committee recommends that vorasidenib may be appropriate for recurrent or residual IDH-mutant grade 2 oligodendroglioma or astrocytoma. Vorasidenib is usually not appropriate for completely resected grade 2 oligodendroglioma or astrocytoma, any grade 3 oligodendroglioma or astrocytoma, or combined with radiotherapy and/or chemotherapy for any grade 2-3 glioma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Radiotherapy and Oncology 医学-核医学

CiteScore

10.30

自引率

10.50%

发文量

2445

审稿时长

45 days

期刊介绍： Radiotherapy and Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes: clinical radiotherapy, combined modality treatment, translational studies, epidemiological outcomes, imaging, dosimetry, and radiation therapy planning, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as data science in radiation oncology and physics aspects relevant to oncology.Papers on more general aspects of interest to the radiation oncologist including chemotherapy, surgery and immunology are also published.